Recruiting

Primary Immunodeficiency

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT03394053

Conditions

Primary Immunodeficiency Disorders

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

Background:

Primary immunodeficiency disorders, or PIDs, are diseases that weaken the immune system. This makes it easier for a person to get sick. Some PIDs are mild and may not be diagnosed until later in life. Other kinds are severe and can be identified shortly after birth. Researchers want to learn more about PIDs by comparing data from relatives and healthy volunteers to people with a PID.

Objective:

To learn more about PIDs, including their genetic causes.

Eligibility:

People ages 0-90 with a PID or their healthy biological relatives the same ages

Healthy volunteers ages 18-75

Design:

Participants will be screened with a medical history, physical exam, and HIV blood test. They may have a pregnancy test.

Participants may repeat the screening tests.

Blood taken at screening will be used for genetic tests and research tests. Participants will be told test results that affect their health. Some blood will be stored for future research.

Adult participants with a PID may have a small piece of skin removed. The area will be numbed. A small tool will take a piece of skin about the size of a pencil eraser.

Researchers may collect fluid or tissue samples from PID participants regular medical care. They will use them for research tests.

Participants with a PID will have 3 follow-up visits over 10 years (for infants, 2 years). Visits will include a physical exam, medical history, and blood draw.

Participants with a PID and their relatives will be called once a year for 10 years. They will talk about how they are feeling and if they have developed any new symptoms or illnesses.

...

Conditions

Primary Immunodeficiency Disorders

Study ID

NCT03394053

Start date

May 30, 2018

Status verified date

Jul 6, 2026

Completion date

Dec 31, 2040

Anticipated

Primary completion date

Dec 31, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Accepted

  • INCLUSION CRITERIA:

1. Subjects must meet one of the following 4 criteria:

1. Patients (age 0-90 years) with a clinical diagnosis of a form of PID (either known or unknown). PID is defined by laboratory and/or clinical findings on two or more occasions that are consistent with a defect in innate or adaptive immunity. Specific PIDs are defined by the International Union of Immunological Societies guidelines. These subjects must also be willing to undergo genetic testing and to allow their biospecimens to be modified into iPS cells. Women of childbearing potential, or who are pregnant or lactating, may be eligible. The volume of blood collected for research purposes will be reduced, and no skin biopsies will be performed for research purposes in consideration of their safety.
2. Infants identified at birth with positive newborn screening for SCID and confirmed to have T-cell lymphocytopenia. These subjects must be willing to undergo genetic testing.
3. Biological relatives (age 0-90 years) of a subject who meets criterion 1a or 1b but who do not have a PID themselves. All relatives must be willing to undergo genetic testing. Women of childbearing potential, or who are pregnant or lactating, may be eligible. The volume of blood collected for research purposes will be reduced in consideration of their safety.
4. Healthy volunteers (age 18-75 years) who are not related to another study subject, who do not have a PID, whose weight is greater than 110 pounds, do not have a history of any heart, lung, or kidney disease, or bleeding disorders, do not have a history of viral hepatitis (B or C), and have a negative HIV screening test.
2. All subjects must be willing to allow their samples to be stored for future research.

EXCLUSION CRITERIA:

1. Subjects with secondary causes of immunodeficiency are excluded from this study. Secondary causes of immunodeficiency include HIV infection and immunodeficiency that is deemed to be secondary to chronic use of immunosuppressive medications or chemotherapeutic agents.
2. Any condition that, in the opinion of the investigator, contraindicates participation in this study.

Study Design

Enrollment

2500 participants

Anticipated

Interventions and Outcome Measures

Arms

Affected Patient

Person with a clinical diagnosis of a PID (age 0-90); either known or unknown as defined by lab and/or clinical findings on 2 or more occasions that are consistent with a defect in innate or adaptive immunity

Normal Volunteer

Persons (age 18-75 years) who are not related to another study subject, who do not have a PID, weight >110lbs, no history of viral hepatitis B or C, have a negative HIV screening test

Relative of Patient

Biological relatives (age 0-90 years) of a subject who meets affected patient criteria, but who do not have a PID themselves

Primary outcome measure

  • Identification of unique clinical phenotypes associated with known genetic causes of PID. [ Time Frame: 10- 15 years ]
  • Identification of genetic variants that are associated with PID. [ Time Frame: 10-15 years ]

Central Contacts and Locations

Central contacts

Luigi D Notarangelo, M.D.

(301) 761-7550luigi.notarangelo2@nih.gov

Locations

Children's National Health System (CNHS)

Recruiting

Washington D.C., District of Columbia, United States, 20010

Contacts

Michael Keller, MD

240-476-5843mkeller@childrensnational.org

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

Contacts

For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

800-411-1222prpl@cc.nih.gov

More Information

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Last update posted

Sep 8, 2026

Last verified

Jul 6, 2026

Keywords

  • SCID
  • Natural Killer (NK) cell deficiency
  • Combined Immunodeficiency
  • T-Cell Lymphocytopenia
  • Of Immune Pathways
  • Natural History

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2026-09-08.